Renal Disease

Nephrology
4
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
Tacrolimus - Prograf® twice daily formulationPhase 41 trial
Active Trials
NCT01334333Completed46Est. Mar 2018
Guerbet
GuerbetFrance - Villepinte
1 program
1
DotaremPhase 31 trial
Active Trials
NCT00980681Terminated13Est. Dec 2010
Hansa Biopharma
Hansa BiopharmaSweden - Lund
1 program
1
IdeS®Phase 1/21 trial
Active Trials
NCT02426684CompletedEst. Nov 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
200 mg Ceftaroline fosamilPhase 11 trial
Active Trials
NCT01664065Completed15Est. Nov 2013
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
Pre-pricing & reimbursement, incident renal disease cohortN/A1 trial
assessmentN/A1 trial
Active Trials
NCT06614712Completed91,628Est. Oct 2025
NCT05967806Completed2,575Est. Aug 2024
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Care Transitions in Renal Disease PatientsN/A1 trial
Active Trials
NCT01842776Unknown3,300Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasTacrolimus - Prograf® twice daily formulation
GuerbetDotarem
Hansa BiopharmaIdeS®
Pfizer200 mg Ceftaroline fosamil
AstraZenecaPre-pricing & reimbursement, incident renal disease cohort
AstraZenecaassessment
AmgenCare Transitions in Renal Disease Patients

Clinical Trials (7)

Total enrollment: 97,577 patients across 7 trials

NCT01334333AstellasTacrolimus - Prograf® twice daily formulation

Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

Start: Nov 2011Est. completion: Mar 201846 patients
Phase 4Completed

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

Start: Sep 2009Est. completion: Dec 201013 patients
Phase 3Terminated

Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

Start: Jun 2015Est. completion: Nov 2017
Phase 1/2Completed
NCT01664065Pfizer200 mg Ceftaroline fosamil

A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects

Start: Feb 2013Est. completion: Nov 201315 patients
Phase 1Completed
NCT06614712AstraZenecaPre-pricing & reimbursement, incident renal disease cohort

OPTIMISE-CKD Study_current Clinical Landscape in Spain

Start: Dec 2024Est. completion: Oct 202591,628 patients
N/ACompleted

A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

Start: Jul 2023Est. completion: Aug 20242,575 patients
N/ACompleted
NCT01842776AmgenCare Transitions in Renal Disease Patients

Care Transitions in Renal Disease Patients

Start: Mar 2013Est. completion: Dec 20143,300 patients
N/AUnknown

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space